METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS
Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; srp |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SUKHATME, MAYUKH VASANT SEELY, LYNN MUDD, JR., PAUL N TANIMOTO, MASATAKA WOLLOWITZ, SUSAN JOHNSON, BRENDAN MARK HIBBERD, MARK RAJASEKHAR, VIJAYKUMAR REDDY |
| description | Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_RS63300B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>RS63300B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_RS63300B13</originalsourceid><addsrcrecordid>eNrjZDDzdQ3x8HcJVvB3UwgJcnUM8fRzVwgNcQ3y9HNVcPN0CvL3BEo6-rkouPq5-AMVB3n6B3sG8zCwpiXmFKfyQmluBjk31xBnD93Ugvz41OKCxOTUvNSS-KBgM2NjAwMnQ2OCCgA99Cbo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS</title><source>esp@cenet</source><creator>SUKHATME, MAYUKH VASANT ; SEELY, LYNN ; MUDD, JR., PAUL N ; TANIMOTO, MASATAKA ; WOLLOWITZ, SUSAN ; JOHNSON, BRENDAN MARK ; HIBBERD, MARK ; RAJASEKHAR, VIJAYKUMAR REDDY</creator><creatorcontrib>SUKHATME, MAYUKH VASANT ; SEELY, LYNN ; MUDD, JR., PAUL N ; TANIMOTO, MASATAKA ; WOLLOWITZ, SUSAN ; JOHNSON, BRENDAN MARK ; HIBBERD, MARK ; RAJASEKHAR, VIJAYKUMAR REDDY</creatorcontrib><description>Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.</description><language>eng ; srp</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220729&DB=EPODOC&CC=RS&NR=63300B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76418</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220729&DB=EPODOC&CC=RS&NR=63300B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SUKHATME, MAYUKH VASANT</creatorcontrib><creatorcontrib>SEELY, LYNN</creatorcontrib><creatorcontrib>MUDD, JR., PAUL N</creatorcontrib><creatorcontrib>TANIMOTO, MASATAKA</creatorcontrib><creatorcontrib>WOLLOWITZ, SUSAN</creatorcontrib><creatorcontrib>JOHNSON, BRENDAN MARK</creatorcontrib><creatorcontrib>HIBBERD, MARK</creatorcontrib><creatorcontrib>RAJASEKHAR, VIJAYKUMAR REDDY</creatorcontrib><title>METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS</title><description>Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDDzdQ3x8HcJVvB3UwgJcnUM8fRzVwgNcQ3y9HNVcPN0CvL3BEo6-rkouPq5-AMVB3n6B3sG8zCwpiXmFKfyQmluBjk31xBnD93Ugvz41OKCxOTUvNSS-KBgM2NjAwMnQ2OCCgA99Cbo</recordid><startdate>20220729</startdate><enddate>20220729</enddate><creator>SUKHATME, MAYUKH VASANT</creator><creator>SEELY, LYNN</creator><creator>MUDD, JR., PAUL N</creator><creator>TANIMOTO, MASATAKA</creator><creator>WOLLOWITZ, SUSAN</creator><creator>JOHNSON, BRENDAN MARK</creator><creator>HIBBERD, MARK</creator><creator>RAJASEKHAR, VIJAYKUMAR REDDY</creator><scope>EVB</scope></search><sort><creationdate>20220729</creationdate><title>METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS</title><author>SUKHATME, MAYUKH VASANT ; SEELY, LYNN ; MUDD, JR., PAUL N ; TANIMOTO, MASATAKA ; WOLLOWITZ, SUSAN ; JOHNSON, BRENDAN MARK ; HIBBERD, MARK ; RAJASEKHAR, VIJAYKUMAR REDDY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_RS63300B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; srp</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SUKHATME, MAYUKH VASANT</creatorcontrib><creatorcontrib>SEELY, LYNN</creatorcontrib><creatorcontrib>MUDD, JR., PAUL N</creatorcontrib><creatorcontrib>TANIMOTO, MASATAKA</creatorcontrib><creatorcontrib>WOLLOWITZ, SUSAN</creatorcontrib><creatorcontrib>JOHNSON, BRENDAN MARK</creatorcontrib><creatorcontrib>HIBBERD, MARK</creatorcontrib><creatorcontrib>RAJASEKHAR, VIJAYKUMAR REDDY</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SUKHATME, MAYUKH VASANT</au><au>SEELY, LYNN</au><au>MUDD, JR., PAUL N</au><au>TANIMOTO, MASATAKA</au><au>WOLLOWITZ, SUSAN</au><au>JOHNSON, BRENDAN MARK</au><au>HIBBERD, MARK</au><au>RAJASEKHAR, VIJAYKUMAR REDDY</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS</title><date>2022-07-29</date><risdate>2022</risdate><abstract>Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; srp |
| recordid | cdi_epo_espacenet_RS63300B1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T06%3A00%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SUKHATME,%20MAYUKH%20VASANT&rft.date=2022-07-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ERS63300B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |